Mesoblast Limited vs Moderna, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Moderna, Inc. is the larger company by market value: $90.1 B against $169 M for Mesoblast Limited, 533 times as much (market caps of Jan 5, 2024 for Mesoblast Limited and Oct 30, 2026 for Moderna, Inc.). Mesoblast Limited's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
- Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $17 M for Mesoblast Limited in the year to June 2025.
- Both made a net loss: $102 M for Mesoblast Limited and $2.8 B for Moderna, Inc.
- Moderna, Inc. keeps more of each dollar of sales: a net margin of -145.2% against -593.8% for Mesoblast Limited.
- Mesoblast Limited's revenue grew faster in its latest fiscal year: +191.5% against -39.9% for Moderna, Inc.
- On the Piotroski F-score, a nine-point test of improving finances, Mesoblast Limited scores 5 and Moderna, Inc. 3.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Mesoblast Limited MSB.AX | Moderna, Inc. MRNA · #275 in the world |
|---|---|---|
| Profile | ||
| Country | 🇦🇺 Australia | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | — | 2010 |
| Size | ||
| Market cap | $169 M* | $90.1 B |
| Revenue | $17 M | $1.9 B |
| Net income | $-102 M▲ best | $-2.8 B |
| Employees | — | 4,700 |
| Valuation | ||
| Price to sales | — | 35.7× |
| Price to book | — | 10.4× |
| Free cash flow yield | — | -2.3% |
| Profitability | ||
| Gross margin | 70.2%▲ best | 55.4% |
| Operating margin | — | -158.1% |
| Net margin | -593.8% | -145.2%▲ best |
| Return on equity | -18.9%▲ best | -28.9% |
| Growth | ||
| Revenue growth | 191.5%▲ best | -39.9% |
| Revenue growth, 3 years a year | 19.0%▲ best | -53.4% |
| Financial strength | ||
| Debt to equity | 0.1× | 0.1×▲ best |
| Cash | ||
| Free cash flow margin | -294.4% | -106.2%▲ best |
| Shareholder returns | ||
| Shareholder yield | — | 0.0% |
| Strength scores | ||
| Piotroski F-score | 5 of 9▲ best | 3 of 9 |
| Altman Z-score zone | — | safe |
| Data as of | Market cap Jan 2024; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Mesoblast Limited or Moderna, Inc.?
Moderna, Inc. is the larger company by market value: $90.1 B against $169 M for Mesoblast Limited, 533 times as much (market caps of Jan 5, 2024 for Mesoblast Limited and Oct 30, 2026 for Moderna, Inc.). Mesoblast Limited's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
Which makes more money, Mesoblast Limited or Moderna, Inc.?
Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $17 M for Mesoblast Limited in the year to June 2025. Both made a net loss: $102 M for Mesoblast Limited and $2.8 B for Moderna, Inc.
Which is more profitable, Mesoblast Limited or Moderna, Inc.?
Moderna, Inc. keeps more of each dollar of sales: a net margin of -145.2% against -593.8% for Mesoblast Limited.
Which is growing faster, Mesoblast Limited or Moderna, Inc.?
Mesoblast Limited's revenue grew faster in its latest fiscal year: +191.5% against -39.9% for Moderna, Inc.
Which is financially stronger, Mesoblast Limited or Moderna, Inc.?
On the Piotroski F-score, a nine-point test of improving finances, Mesoblast Limited scores 5 and Moderna, Inc. 3.
More about Mesoblast Limited
More about Moderna, Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.